For Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, 2026 promises to be a transformative year as it awaits a key data readout for its flagship asset, Xpovio, in the coming months.
Xpovio (selinexor) belongs to the drug class called selective inhibitors of nuclear export (SINE). It works by targeting a specific protein complex called XPO1, which is responsible for removing tumor suppressor proteins from the cell nucleus. This leads to the accumulation of XPO1 inside the cell, which reinitiates and amplifies its function, leading to apoptosis (cell death) of cancer cells, while largely sparing normal cells. (Source: Drugs.com)
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com